{"id":"ct-p59","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CT-P59 is a monoclonal antibody that targets the SARS-CoV-2 spike protein, preventing the virus from entering host cells. This mechanism of action is similar to other COVID-19 treatments that target the spike protein.","oneSentence":"CT-P59 is a COVID-19 treatment that works by binding to the SARS-CoV-2 spike protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:51.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT04602000","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-10-05","conditions":"SARS-CoV-2 Infection","enrollment":1642},{"nctId":"NCT04593641","phase":"PHASE1","title":"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-09-04","conditions":"SARS-CoV-2 Infection","enrollment":18},{"nctId":"NCT04525079","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-07-18","conditions":"SARS-CoV-2 Infection","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["regdanvimab"],"phase":"phase_2","status":"active","brandName":"CT-P59","genericName":"CT-P59","companyName":"Celltrion","companyId":"celltrion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-P59 is a COVID-19 treatment that works by binding to the SARS-CoV-2 spike protein. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}